Precirix is developing precision radiopharmaceuticals that utilize camelid single-domain antibodies labeled with radiometals to target Fibroblast Activation Protein (FAP) in cancer treatment. This approach aims to provide a first-in-class alpha-emitting targeted radiotherapy for a broad range of tumors, addressing the need for more effective cancer therapies.
Funding
$88.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCJCFounders
Product
Problem
Many solid tumors are difficult to treat due to the protective microenvironment created by cancer-associated fibroblasts. Current cancer therapies often lack the ability to selectively target these fibroblasts, leading to off-target effects and limited efficacy. There is a need for more precise cancer therapies that can specifically target the tumor microenvironment.
Solution
Precirix is developing precision radiopharmaceuticals that target Fibroblast Activation Protein (FAP), a protein highly expressed in the tumor microenvironment. The company utilizes camelid single-domain antibodies labeled with radiometals to selectively deliver radiation to FAP-expressing cells. This approach aims to provide a first-in-class alpha-emitting targeted radiotherapy for a broad range of solid tumors, improving treatment efficacy while minimizing damage to healthy tissues.
Target Audience
The primary target audience includes cancer patients with solid tumors expressing FAP, as well as oncologists and medical professionals seeking more effective and targeted cancer therapies.
Features
- Camelid single-domain antibody platform for targeted delivery of radiometals
- Lead program targeting Fibroblast Activation Protein (FAP)
- Utilizes alpha-emitting radioisotopes for potent cytotoxic effect
- Potential for pan-tumor application across various solid tumor types
- Ongoing research on multiple isotopes, linker technology, and combination therapies